Adicet Bio Inc. (ACET)
0.62
0.02 (3.09%)
At close: Apr 23, 2025, 3:59 PM
Adicet Bio Revenue Breakdown
| Period Ending | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Human Health Revenue | 84.98M | 80.85M | 374.51M | 91.93M | 103.47M | 106.02M | 113.71M | 99.82M | 53.98M | 47.89M | 52.73M | 58.78M | 59.05M | 57.48M | 64.45M | 56.3M | 55.42M | 49.08M | 47.76M | 33.95M | 39.82M | 38.69M | 36.3M | 29.85M | 26.41M |
| Human Health Revenue Growth | +5.11% | -78.41% | +307.41% | -11.15% | -2.40% | -6.77% | +13.92% | +84.91% | +12.72% | -9.18% | -10.29% | -0.45% | +2.72% | -10.82% | +14.47% | +1.59% | +12.93% | +2.76% | +40.69% | -14.74% | +2.90% | +6.60% | +21.60% | +13.03% | n/a |
| Performance Chemicals Revenue | 36.63M | 44.71M | 177.99M | 50.87M | 34.13M | 42.66M | 44.72M | 46.49M | 34.76M | 39.51M | 40.18M | 53.3M | 38.33M | 37.66M | 43.94M | 48.94M | 35.76M | 43.75M | 49.14M | 43.04M | 39.21M | 42.14M | 52.8M | 44.32M | 44.73M |
| Performance Chemicals Revenue Growth | -18.08% | -74.88% | +249.89% | +49.03% | -19.99% | -4.60% | -3.81% | +33.77% | -12.04% | -1.66% | -24.62% | +39.05% | +1.79% | -14.29% | -10.22% | +36.86% | -18.25% | -10.98% | +14.17% | +9.76% | -6.95% | -20.18% | +19.12% | -0.92% | n/a |
| Pharmaceutical Ingredients Revenue | 42.04M | 38.85M | 158.85M | 43.2M | 33.63M | 36.58M | 36.19M | 43.82M | 36.82M | 40.62M | 42.52M | 45.84M | 34.3M | 38.36M | 38.19M | 40.55M | 32.58M | 37.98M | 42.68M | 47.84M | 37.48M | 48.42M | 61.78M | 39.78M | 40.61M |
| Pharmaceutical Ingredients Revenue Growth | +8.22% | -75.54% | +267.71% | +28.46% | -8.06% | +1.06% | -17.41% | +19.03% | -9.36% | -4.47% | -7.26% | +33.67% | -10.60% | +0.44% | -5.81% | +24.46% | -14.21% | -11.02% | -10.79% | +27.65% | -22.60% | -21.61% | +55.27% | -2.03% | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2017 | Jun 30, 2016 | Jun 30, 2015 | Jun 30, 2014 | Jun 30, 2013 | Jun 30, 2012 |
|---|---|---|---|---|---|---|
| United States Revenue | 483.68M | 34.58M | 27.33M | 26.16M | 28.4M | 25.28M |
| United States Revenue Growth | +1298.68% | +26.54% | +4.47% | -7.90% | +12.36% | n/a |
| Asia Pacific Revenue | 29.79M | 30.18M | 27.98M | 29.41M | n/a | n/a |
| Asia Pacific Revenue Growth | -1.28% | +7.87% | -4.88% | n/a | n/a | n/a |
| France Revenue | 35.8M | 76.67M | 69.89M | 84.02M | n/a | n/a |
| France Revenue Growth | -53.31% | +9.70% | -16.82% | n/a | n/a | n/a |
| Germany Revenue | 79.11M | 16.22M | 14.66M | 14.87M | n/a | n/a |
| Germany Revenue Growth | +387.79% | +10.65% | -1.43% | n/a | n/a | n/a |
| Netherlands Revenue | 9.95M | n/a | n/a | n/a | n/a | n/a |
| Netherlands Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 6.9M | 6.95M | 5.32M | 5.12M | 6.63M | 6.53M | 6.57M | 6.55M | 6.42M | 6.53M | 6.8M | 6.35M | 5.21M | 5.03M | 5.63M | 5.08M | 7.74M | 7.42M | 2.52M | 2.62M | 1.85M | 2.09M | 2.13M | -47.16M | 2.27M | 2.27M | 2.09M | -53.75M | 609K | 1.21M | 26.52M | 28.07M | 21.02M | 14.79M | 19.5M | 19.25M | 17.63M | 8.89M | 19.07M |
| Selling, General, and Administrative Revenue Growth | -0.69% | +30.53% | +4.01% | -22.84% | +1.61% | -0.58% | +0.24% | +2.10% | -1.75% | -4.00% | +7.07% | +21.85% | +3.74% | -10.75% | +10.91% | -34.43% | +4.34% | +193.94% | -3.77% | +42.01% | -11.75% | -1.69% | -104.51% | -2180.11% | -0.04% | +8.31% | -103.90% | -8926.44% | -49.50% | -95.45% | -5.53% | +33.52% | +42.18% | -24.16% | +1.31% | +9.15% | +98.37% | -53.38% | n/a |
| Research and Development Revenue | 26.25M | 25.9M | 23.9M | 24.76M | 26.17M | 28.36M | 26.76M | 25.02M | 16.57M | 16.18M | 13.48M | 14.66M | 11.93M | 10.62M | 11.74M | 9.68M | 8.94M | 8.68M | 7.03M | 6.52M | 6.33M | 5.83M | 5.01M | 24.18M | 6.76M | 11.85M | 8.11M | 9.95M | 3.33M | 2.94M | 2.61M | 1.34M | 1.05M | 1.66M | 2.32M | 2.53M | 1.43M | 2M | 2.1M |
| Research and Development Revenue Growth | +1.36% | +8.39% | -3.48% | -5.38% | -7.74% | +6.00% | +6.96% | +50.97% | +2.42% | +19.99% | -8.02% | +22.91% | +12.34% | -9.60% | +21.27% | +8.29% | +3.07% | +23.36% | +7.82% | +3.03% | +8.65% | +16.31% | -79.28% | +257.40% | -42.89% | +46.13% | -18.55% | +198.59% | +13.41% | +12.73% | +94.41% | +27.71% | -36.63% | -28.55% | -8.38% | +76.99% | -28.46% | -4.85% | n/a |